Abdelwahab Siddig Ibrahim, Moni Sivakumar S, Taha Manal Mohamed Elhassan, Sahli Khaled A, Alqhtani Hatem Ahmed Salem, Farasani Moath Mohamed, Qadri Marwa, Alarifi Abdulaziz, Khardali Amani, Alsaadi Khulud Hamoud, Farasani Abdullah, Khamjan Nizar A, Al-Shamsi Humaid, Moshi Jobran M, Alshahrani Saeed, Salawi Ahmed, Assiri Ahmad, Ibrahim Ayah
Health Research Centre, Jazan University, 45142, Jazan, Saudi Arabia.
Department of Pharmaceutics, College of Pharmacy, Jazan University, 45142, Jazan, Saudi Arabia.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04401-7.
Monoclonal Antibodies and Breast Cancer Research (MABCR) has progressed substantially, particularly in the areas of HER2-positive and triple-negative breast cancer. However, a comprehensive synthesis of global trends, influential contributors, and emerging research areas remains lacking. This study presents a bibliometric analysis of MABCR, highlighting major research trajectories, key publications, and evolving themes. Using data from the Scopus database spanning 1972 to 2024 and applying a multistep search strategy cross-validated with MeSH terms, 14,764 English-language original research articles were identified across 2125 sources. Non-research documents, duplicates, and retractions were excluded. Quantitative analysis was conducted using Bibliometrix, VOSviewer, and CiteSpace. The annual publication growth rate was 17.8%. The USA and China were the leading contributors, while Breast Cancer Research and Treatment emerged as the most prolific journal. Influential authors such as Slamon, Baselga, and Hortobagyi were identified based on publication volume, H-index, and citation impact. Co-citation analysis revealed major thematic clusters including HER2-positive and triple-negative breast cancer, trastuzumab deruxtecan, and the integration of machine learning in MABCR. Emerging areas of interest include HER2-low subtypes and tumor microenvironment profiling using radiomics and multi-omic approaches. This analysis provides a structured overview of MABCR, offering valuable insights to guide future research and foster innovation in precision oncology.
单克隆抗体与乳腺癌研究（MABCR）已经取得了长足的进展，尤其是在HER2阳性和三阴性乳腺癌领域。然而，目前仍缺乏对全球趋势、有影响力的贡献者以及新兴研究领域的全面综合分析。本研究对MABCR进行了文献计量分析，突出了主要研究轨迹、关键出版物和不断演变的主题。利用Scopus数据库中1972年至2024年的数据，并采用与医学主题词（MeSH）交叉验证的多步骤搜索策略，从2125个来源中识别出14764篇英文原创研究文章。排除了非研究文献、重复文献和撤稿文献。使用Bibliometrix、VOSviewer和CiteSpace进行了定量分析。年发表增长率为17.8%。美国和中国是主要贡献国，而《乳腺癌研究与治疗》是发表量最多的期刊。根据发表量、H指数和引用影响力等指标，确定了Slamon、Baselga和Hortobagyi等有影响力的作者。共被引分析揭示了主要的主题聚类，包括HER2阳性和三阴性乳腺癌、曲妥珠单抗德鲁替康以及机器学习在MABCR中的整合。新兴的研究领域包括HER2低表达亚型以及使用放射组学和多组学方法对肿瘤微环境进行分析。本分析提供了MABCR的结构化概述，为指导未来研究和推动精准肿瘤学的创新提供了有价值的见解。
